Galectins News and Research

RSS
Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial

Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial

Pro-Pharmaceuticals second-quarter net loss applicable to common stock decreases to $2.5 million

Pro-Pharmaceuticals second-quarter net loss applicable to common stock decreases to $2.5 million

Modified Citrus Pectin holds promise against prostate cancer

Modified Citrus Pectin holds promise against prostate cancer

Boston Therapeutics submits structure, function claims of SUGARDOWN to FDA

Boston Therapeutics submits structure, function claims of SUGARDOWN to FDA

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Pro-Pharmaceuticals reports net loss applicable to common stock of $2.8M for first-quarter 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $2.8M for first-quarter 2010

Pro-Pharmaceuticals completes $6 million private placement with 10X Fund

Pro-Pharmaceuticals completes $6 million private placement with 10X Fund

Pro-Pharmaceuticals closes $310,000 private placement tranche

Pro-Pharmaceuticals closes $310,000 private placement tranche

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Pro-Pharmaceuticals announces closing of $335,000 tranche of private placement

Pro-Pharmaceuticals announces closing of $335,000 tranche of private placement

Proteins found in intestines can recognize and kill bacteria that have human blood type molecules

Proteins found in intestines can recognize and kill bacteria that have human blood type molecules

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Pro-Pharmaceuticals announces closure of $325,000 tranche of private placement

Pro-Pharmaceuticals announces closure of $325,000 tranche of private placement

Pro-Pharmaceuticals announces financial results for the third quarter and first nine months of fiscal 2009

Pro-Pharmaceuticals announces financial results for the third quarter and first nine months of fiscal 2009

Pro-Pharmaceuticals closes $325,000 tranche of private placement; total raised to $3.8 million

Pro-Pharmaceuticals closes $325,000 tranche of private placement; total raised to $3.8 million

Research details role of galectin-3 in heart failure

Research details role of galectin-3 in heart failure

FDA grants IND for Davanat to treat breast cancer patient

FDA grants IND for Davanat to treat breast cancer patient